RESEARCH ARTICLE A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal Published in Modern Pathology [...]
RIP THE GREAT ARETHA FRANKLIN Aretha Franklin, the Queen of Soul, passed away from neuroendocrine cancer (NETs) of the pancreas, the very same cancer that killed Apple [...]
In March CNETS Canada reached out to the patient community through an online, anonymous survey to gather feedback and input on setting the research priorities for CNETS Canada sponsored grants [...]
REQUEST FOR PATIENT INPUT - TREATMENT WITH Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera) Lutetium-177 (177Lu)-DOTATATE (trade name Lutathera), is a peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogues (peptides). [...]
Une approche novatrice contre le cancer à l'Hôtel-Dieu de Québec « Une nouvelle approche médicale attire à Québec des Canadiens, et même des Américains, atteints d'une forme rare de cancer. Le traitement [...]
Dear Friends, This May 27th I will once again have the honour of being Team Captain for Team Zebra for Carcinoid Neuroendocrine Tumour Society (CNETS) Canada. I will be running the Half Marathon [...]
Patient Groups send a strong message to the Federal Minister of Health: Patient voices must be heard. We ask the @CDNMinHealth to halt the review of drug prices and move to [...]
Somatuline Autogel is the first and only somatostatin analog (SSA) approved in Canada to treat enteropancreatic neuroendocrine tumours and carcinoid syndrome. Februaury 13th, 2018 - Health Canada announced the approval [...]
CNETS Canada Montreal Support Group Leaders Donna Hillier, Daniel Opoku and volunteer Marie-Anne Risdon set up a kiosk at the Ceders Cancer Foundation - CEDARS CANSUPPORT WORLD CANCER DAY, providing [...]
We are pleased to announce that Ontario Drug Benefit (ODB) has listed Afinitor (everolimus) for the treatment of patients with GI/Lung NET, effective November 20, 2017 through the Exceptional Access [...]